MedPath

Effect of Sporlac on Blood Sugar Levels

Phase 3
Completed
Conditions
Health Condition 1: null- Diabetes
Registration Number
CTRI/2017/12/010802
Lead Sponsor
Sanzyme Private Limited
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
4
Inclusion Criteria

1.Healthy adult males between 40 and 60 years of age

2.Subjects providing written informed consent

Exclusion Criteria

1.Subjects with impaired glucose tolerance

2.Subjects with known allergy to Sporlac or its constituents

3.Subjects with any disorder that might affect their GI function

4.Patients with active liver or kidney disease

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To assess the effect of pre-treatment with Sporlac on fasting blood sugar and glycaemic response to foodTimepoint: 9 Days
Secondary Outcome Measures
NameTimeMethod
To assess the safety of Sporlac in healthy individualsTimepoint: 9 Days
© Copyright 2025. All Rights Reserved by MedPath